title: Clinical and pathological findings in prostates following intravesical bacillus Calmette-Guerin instillations.
abstract: The prostates of 36 patients who were treated with intravesical bacillus Calmette-Guerin were evaluated by digital rectal examination and transrectal ultrasonography. When abnormal palpatory and/or ultrasonographic findings were detected, core needle biopsies from the suspicious areas were performed. Of the 36 patients 20 underwent biopsies of the prostate. Pathological findings revealed typical granulomas in 8 patients (3 caseating and 5 noncaseating multifocal granulomas). Nonspecific chronic prostatitis was noted in 4 patients and benign prostatic hyperplasia was noted in 8. The number of bacillus Calmette-Guerin instillations ranged from 6 to 19. The interval from initiation of therapy to biopsy ranged from 1.5 to 14.5 months. Caseating granulomas were found during the early course of bacillus Calmette-Guerin instillations (1.5 to 3.0 months), whereas noncaseating granulomas were detected at later stages (4 to 14.5 months). These findings present a high incidence of granuloma formation in patients treated with intravesical bacillus Calmette-Guerin. The duration of therapy is a determinant factor in the induction of granuloma type.
authors.affiliation: Department of Urology, Beilinson Medical Center, Tel Aviv University Sackler School of Medicine, Petah Tiqva, Israel.
authors.forename: E
authors.initials: E
authors.lastname: Mukamel
authors.forename: M
authors.initials: M
authors.lastname: Konichezky
authors.forename: D
authors.initials: D
authors.lastname: Engelstein
authors.forename: S
authors.initials: S
authors.lastname: Cytron
authors.forename: A
authors.initials: A
authors.lastname: Abramovici
authors.forename: C
authors.initials: C
authors.lastname: Servadio
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D001707:Biopsy, Needle; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006099:Granuloma / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D011467:Prostate / Q000473:pathology*; D011469:Prostatic Diseases / Q000209:etiology* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine